Navigation Links
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE: BMY) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology and Licensing. He will report to Dr. Elliott Sigal, chief scientific officer and president, Research and Development.

"I am delighted Jeremy has joined our R&D organization at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future," said Dr. Sigal. "Jeremy's extensive global network in the pharmaceutical, biotechnology and venture industries will help ensure that we remain a leader in forging creative partnerships to advance the development of novel medicines."

Prior to joining Bristol-Myers Squibb, Dr. Levin served as Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research. In that capacity, he and his team secured hundreds of collaborations in more than 20 countries since 2003. Prior to his tenure at Novartis, Dr. Levin held leadership positions in several biotechnology companies, including Physiome Sciences, Inc. and Cadus Pharmaceutical Corporation. He also was managing director of Perseus Capital LLC, a life sciences venture fund. He has served on the executive committees and boards of several public biosciences companies, as well as the Executive Committee of BIO and the boards of the Biotechnology Institute and the New York Biotechnology Association.

"I am excited about the tremendous opportunity at Bristol-Myers Squibb," said Dr. Levin. "I am especially looking forward to working with Elliott, his team and all the outstanding people at this company. I will look to aggressively complement Bristol-Myers Squibb's world class internal team, capabilities and pipeline with the best science and medicines around the globe."

Dr. Levin received a B.A. (First Class Honors) in Zoology, and M.A. and Doctorate (D.Phil.) in Cell Biology and Chromatin Structure from the University of Oxford, as well as a Medical Degree (MB BChir) from the University of Cambridge. He practiced as a physician in internal medicine in several university hospitals, including Hammersmith Hospital in London. In 2005, Dr. Levin was awarded the Albert Einstein Award for Outstanding Achievement in the Life Sciences.

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Rat joins list of cloned animals
3. Richard Gere Joins Indian Stars For Fight Against AIDS
4. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
5. Anoushka Joins Hands With WFP to Feed the Poor
6. India Joins Hands With Global Body for Vaccine Research
7. Another Statewide Organization Joins the Fight Against Assisted Suicide
8. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
9. Senior drug card saves little
10. Reducing Depression In Seniors
11. A sharp increased in senior citizens: set to outpace children.
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... second medical opinion process, participated in the 61st annual Employee Benefits Conference. The ... and took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference ...
(Date:11/26/2015)... ... 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk ... system efficiency and reliability. , The new Q-Suite 6 platform is based on the ... locking itself into a specific piece of software for many key components of the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology: